Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | KIF5B | P33176 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 12/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.80 |
| ▸ | FLT4 | P35916 | 9/20 | 0.76 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.70 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.70 |
| ▸ | TEK | Q02763 | 2/20 | 0.70 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.70 |
| ▸ | PLK4 | O00444 | 1/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.70 |
| ▸ | GAK | O14976 | 1/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7864775 | 0.99 | KDR (0.98) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL19006858 | 0.93 | KDR (0.87) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL20355323 | 0.93 | KDR (0.86) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL15946890 | 0.92 | KDR (0.84) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL7864780 | 0.91 | KDR (0.83) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL5241456 | 0.91 | KDR (0.83) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL156289 | 0.91 | KDR (0.83) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL5237480 | 0.90 | KDR (0.82) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL14964748 | 0.90 | KDR (0.82) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL1468281 | 0.90 | KDR (0.82) | KDREGFRRETKIF5BFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038049-B2 | Haloanilino quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2005-04-07 | — | — | US | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | disclosed |
| US-6358962-B2 | ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS | PARKER HUGHES INSTITUTE | 2002-03-19 | — | — | US | disclosed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885EGFR 1931/4885RET 1370/4885 |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | KDR 2810/4885EGFR 3336/4885RET 2800/4885 |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885EGFR 1931/4885RET 1370/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885EGFR 1931/4885RET 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.